EyePoint, a Watertown, Massachusetts, drug developer focused on retinal diseases, plans to cut about 53% of its workforce after a pivotal trial of its lead drug candidate in wet age-related macular degeneration missed its primary goal. The company announced the plan Monday, Oct.
